Get the Daily Brief
Latest Biotech News
Roche’s acquisition of PathAI to scale digital pathology diagnostics
Roche agreed to acquire PathAI in a deal potentially worth up to $1.05 billion, aiming to expand its digital pathology capabilities and accelerate AI-enabled diagnostic workflows. The structure...
Cell therapy manufacturing automation: Cellular Origins teams with Immatics
Cellular Origins agreed to collaborate with Immatics to use the companies’ shared automated manufacturing capabilities, incorporating Cellular Origins’ Constellation mobile robotic platform into...
Big pharma still funding AI diagnostics: Immunai expands AstraZeneca deal to $37.5M
Immunai expanded its collaboration with AstraZeneca to extend usage of its AMICA-OS AI platform across oncology drug development. The parties described the deal as worth up to $37.5 million,...
Tempus convertible notes: $350M funding plan to repay debt and invest
Tempus AI announced plans for a private placement of $350 million in convertible senior notes, with net proceeds intended primarily for debt repayment and funding corporate initiatives. The...
Sarepta revenue holds up, but Elevidys declines and shares slide
Sarepta Therapeutics reported that Elevidys (gene therapy) net product revenue beat Wall Street expectations in its latest quarter, but sales continued to decline as the company navigates ongoing...
BillionToOne expects Unity Confirm to drive more prenatal uptake
BillionToOne told investors it expects its Unity Confirm confirmation test to further differentiate its prenatal genetics suite and increase uptake of its Unity Aneuploidy screening platform. The...
Cancer diagnostics startup Imagenomix raises seed to scale AI histopathology
Imagenomix, an NYU Langone Health spinout building AI-driven cancer diagnostics from standard histopathology images, raised $3.2 million in seed funding. The round was led by Modi Ventures with...
R&D and venture funding: Brano Therapeutics closes $6.8M seed for HFpEF
Singapore-based Brano Therapeutics secured $6.8 million in seed funding to advance new heart failure treatments focused on HFpEF, a condition still marked by limited therapy options. The financing...
CNS M&A: Angelini expands into rare neurological disease in the US
Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for about $4.1 billion in cash, adding a portfolio of three FDA-approved rare-disease CNS medicines and a larger US commercial footprint....
Duchenne trial data roil investors at Entrada; competition pressures on
Entrada Therapeutics’ shares fell sharply after early Duchenne muscular dystrophy data for ENTR-601-44 fell short of expectations on dystrophin production. The Phase 1/2 results in exon...
Digital pathology consolidation: Roche to acquire PathAI
Roche agreed to acquire PathAI, a Boston-based digital pathology firm, in a deal potentially worth up to $1.05 billion. Roche will pay $750 million upfront and make milestone payments up to $300...
Precision oncology M&A and portfolio building: UCB buys Candid for T-cell engager expansion
UCB agreed to acquire Candid Therapeutics for up to $2.2 billion, aiming to expand its T-cell engager antibody pipeline for autoimmune and inflammatory indications. The deal adds Candid’s lead...
Cystic fibrosis and pancreatic insufficiency: Blackstone backs Anagram with $250M
Blackstone Life Sciences will invest $250 million into Anagram Therapeutics to target the complication burden of cystic fibrosis. The company’s approach is aimed at reducing the daily pill load...
Digital diagnostics and MRD momentum: Tempus AI convertible notes and revenue growth
Tempus AI said it will raise $350 million in convertible senior notes in a private placement, citing planned use of proceeds to repay existing loans and fund corporate purposes including...
GSK secures cardiometabolic RNAi: $1B-plus siRNA license for SiranBio asset
GSK licensed exclusive worldwide rights to SiranBio’s siRNA SA-030 in a deal potentially worth up to $1 billion. The program targets ALK7 with the intent to reduce abdominal fat and improve...
Ophthalmology dealmaking: Bayer acquires Perfuse for up to $2.45B
Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, strengthening its ophthalmology pipeline with a mid-stage implant program. The transaction structure includes $300 million...
Oncology financing and diagnostics scaling: BillionToOne Unity Confirm push
BillionToOne reported a major Q1 revenue increase driven by prenatal testing volume growth and set expectations for its Unity Confirm follow-on assay to further differentiate the portfolio. The...
Cancer screening commercial growth: Grail pushes Galleri volume and EHR integration
Grail reported Q1 revenue growth of 28% year over year, driven by continued expansion of its Galleri multi-cancer screening test. Revenue for the quarter reached $40.8 million, with Galleri...
Big Pharma M&A: Angelini’s U.S. rare-neurology push
Angelini Pharma agreed to buy Catalyst Pharmaceuticals in a cash deal valued at about $4.1 billion, adding three FDA-approved rare neurological medicines and a U.S. commercial platform. The offer...
Ophthalmology M&A: Bayer buys implant drugmaker Perfuse
Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, starting with a $300 million upfront payment, to expand its ophthalmology pipeline. Perfuse’s lead program, PER-001, is a...